Company’s Ac-225 being used in human clinical trials around world
TerraPower Isotopes (TPI), part of the Bill Gates-founded advanced nuclear reactor company TerraPower, has broken ground on its flagship Bellwether Laboratory actinium-225 (Ac-225) manufacturing facility in the Bellwether District of Philadelphia.
The company said the groundbreaking marked the next major milestone in its efforts to establish a state-of-the-art East Coast manufacturing presence dedicated to the production of one of the rarest and most medically promising radioisotopes to support the development of targeted alpha therapy and precision medicine.
TPI’s Bellwether Laboratory, combined with the company’s expanding capacity in its Everett, Washington laboratory, will increase the global Ac-225 production capacity twentyfold – positioning TPI as the premier global distributor of Ac-225 and directly addressing a critical supply constraint that has limited the advancement of targeted alpha therapies for cancer treatment.
The company’s Ac-225 is being used in human clinical trials around the world, supporting the development of targeted alpha therapies – a rapidly growing class of precision cancer treatments that couple radioisotopes with targeting molecules to deliver localised doses of radiation directly to cancer cells.
TerraPower recently announced the official start of construction on its flagship Natrium nuclear plant, which is on track to be the first utility-scale advanced nuclear power plant in the US.
